Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance

Figure 6 A: Percentage of patients with HBV DNA responses at months 1, 2, 3, 6, 9, and 12 after treatment with lamivudine (gray bars) and adefovir (black bars). ^aP < 0.05 vs ADV; B: Time to HBV DNA response during 12 mo of lamivudine (left) and adefovir (right) treatments. HBV DNA responses appeared in 36 patients with lamivudine treatment and in 30 patients with adefovir treatment. HBV DNA response was slower when patients were treated with adefovir (median 1.5 mo) than with lamivudine (median 1 mo; P < 0.05). Time to HBV DNA response after lamivudine or adefovir treatment in each patient is shown as ● and ▲, respectively. Horizontal bars (—) represent median times to HBV DNA response. LMV: lamivudine; ADV: adefovir dipivoxil.